Kagocel tablets 12mg, No. 10

Kagocel tablets 12mg, No. 10; 'KagocelЃ is used in adults and children aged 3 years and older as a preventive and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.

Inside, regardless of the meal.
For the treatment of influenza and acute respiratory viral infections, adults are prescribed in the first two days - 2 tablets 3 times a day, in the next two days - one tablet 3 times a day. In total, the course - 18 tablets, the duration of the course - 4 days.
Prevention of influenza and acute respiratory viral infections in adults is carried out in 7-day cycles: two days - 2 tablets once a day, a break for 5 days, then repeat the cycle. The duration of the preventive course is from one week to several months.

Kagocel 12 mg

Excipients: potato starch - 10 mg, calcium stearate - 0.65 mg, Ludipress (composition: lactose monohydrate - from 91% to 95%, povidone (Kollidon 30) - from 3% to 4%, crospovidone (Kollidon CL) - from 3 % up to 4%) - until a tablet weighing 100 mg is obtained.

• Pregnancy;

• lactation period (breastfeeding);

• children under 3 years old;

• lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

• hypersensitivity to the components of the drug.

pharmachologic effect

The active substance is the sodium salt of the copolymer (1> 4) -6-0-carboxymethyl -? - D-glucose, (1> 4) -? - D-glucose and (21> 24) -2,3,14,15 , 21,24,29,32-octahydroxy-23- (carboxymethoxymethyl) -7,10-dimethyl-4,13-di (2-propyl) -19,22,26,30,31-pentaoxaheptacyclo [23.3.2.216. 20.05.28.08.27.09.18.012.17] dotriaconta-1,3,5 (28), 6.8 (27), 9 (18), 10.12 (17), 13,15-decaene.

It causes the formation in the human body of the so-called late interferons, which are a mixture of alpha and beta interferons, which have high antiviral activity. KagocelЃ induces the production of interferons in almost all populations of cells involved in the antiviral response of the body: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When a single dose of KagocelЃ is ingested, the titer of interferons in the blood serum reaches its maximum values ??after 48 hours. The body's interferon response to the introduction of Kagocel is characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of the accumulation of interferons in the intestine when taking the drug inside does not coincide with the dynamics of the titers of circulating interferons.In the blood serum, the production of interferons reaches high values ??only 48 hours after taking Kagocel, while in the intestine, the maximum production of interferons is noted already after 4 hours.

When administered in therapeutic doses, KagocelЃ is non-toxic and does not accumulate in the body. The drug does not possess mutagenic and teratogenic properties, is not carcinogenic and does not have an embryotoxic effect.

The greatest efficiency in the treatment with the drug KagocelЃ is achieved when it is prescribed no later than the 4th day after the onset of an acute infection. For prophylactic purposes, the drug can be used at any time, incl. and immediately after contact with the infectious agent.

Pharmacokinetics

Absorption and distribution

When taken orally, about 20% of the administered dose of the drug enters the general bloodstream. 24 hours after administration into the body, the drug accumulates mainly in the liver, to a lesser extent - in the lungs, thymus, spleen, kidneys, lymph nodes. Low concentration is observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of kagocel in the brain is explained by the high molecular weight of the drug, which makes it difficult for its penetration through the BBB. In blood plasma, the drug is mainly in bound form: with lipids - 47%, with proteins - 37%. The unbound part of the drug is about 16%.

With daily repeated administration of Kagocel, Vd fluctuates widely in all studied organs. The accumulation of the drug in the spleen and lymph nodes is especially pronounced.

Withdrawal

It is excreted from the body, mainly through the intestines: after 7 days after ingestion, 88% of the administered dose is excreted from the body, incl. 90% through the intestines and 10% through the kidneys. The drug was not detected in the exhaled air.

Side effect

Possibly: allergic reactions.

If any of these side effects are aggravated, or the patient has noticed any other side effects, he should inform the doctor about it.

Application during pregnancy and lactation

Due to the lack of necessary clinical data, the drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Application in children

Contraindicated for use in children under 3 years of age.

special instructions

To achieve a therapeutic effect, taking the drug KagocelЃ should be started no later than the 4th day from the onset of the disease.

Influence on the ability to drive vehicles and mechanisms

The effect of the drug on the ability to drive vehicles, mechanisms has not been studied.

Overdose

Treatment: in case of an accidental overdose, it is recommended to prescribe an abundant drink, induce vomiting.

Drug interactions

The drug KagocelЃ combines well with other antiviral drugs, immunomodulators and antibiotics (additive effect).